Biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner Lundbeck. The current development products include tozadenant for Parkinson's disease, which is in Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver.
Biotie's shares are listed on NASDAQ Helsinki (BTH1V) and ADS's on Nasdaq Stock Market LLC (BITI).
Acorda Therapeutics, Inc. holds, following the completion of a Tender Offer, more than 90 percent of the shares in Biotie (excluding treasury shares) and will initiate arbitral proceedings as provided in the Finnish Limited Liability Companies Act to effect the redemption of the Biotie shares held by minority shareholders.
16 May, 2016